JPMorgan upgrades Sonova stock rating on valuation reset

JPMorgan upgraded Sonova to Overweight and raised its price target to CHF163 from CHF158 ahead of FY25/26 results, noting the company confirmed the lower end of its FY25/26 guidance. The bank sees Wholesale upside offset by Retail and Cochlear Implants downside, flagged ~200bps of margin accretion from the Consumer exit not yet reflected in consensus, and said consensus is too low for FY25/26 but too aggressive for FY26/27. Valuation has compressed from ~30x to ~17.5x (current reported P/E ~20.13) and the stock is trading near its 52-week low of $42.26, down ~24% over the past year; InvestingPro flags the name as potentially undervalued.

Analysis

The market reaction has likely priced a too-simple narrative: execution slippage + currency pressure = permanent multiple compression. That’s a plausible near-term explanation, but it ignores margin mechanics from a portfolio reshuffle — moving low-margin consumer SKUs out of the mix can lift headline margins materially even if organic growth stays muted, creating a convex EPS recovery if wholesalers scale faster than retail declines.

Second-order beneficiaries are not just direct competitors but distribution and sensor suppliers that feed large-volume, lower-ASP channels; conversely, premium retail networks and implant-focused specialists may see demand reallocated and margin pressure. FX translation volatility is the amplifier here: small percentage moves in CHF/EUR versus reporting currencies can swing EPS by high single-digit percentages, so headline beats or misses over the next 6–12 months will be as much currency-driven as operational.

Primary risks are execution of the commercial transition and product-cycle timing — a prolonged uptake gap between channel mix changes and replacement demand will extend the multiple reset. A contrarian case: if management delivers cost rationalization and wholesale volume scales, the valuation could re-rate before top-line growth returns, making defined-risk option structures attractive for asymmetric upside exposure over 6–18 months.

Key Decisions for Investors

• Long SOON.SW / SONVY (6–12 month horizon): size 2–4% of portfolio. Use a buy-and-hold equity stake funded gradually on weakness to avoid front-running FX moves. Target asymmetric payoff: add on 10–15% pullbacks; trim half on a 30–40% rally. Stop-loss 20% absolute from entry to limit idiosyncratic execution risk.
• Options alternative — long-dated bull-call spread (12 months): buy 12-month call ~5–10% ITM and sell a 12-month call ~40–50% OTM to finance premium. This caps downside while preserving most of upside from a re-rate; attractive if you believe margin re-leveraging precedes sustainable growth.
• Pair trade to isolate company-specific risk (6–12 months): go long SOON.SW (2%) and short COH (Cochlear) or GN (equal notional) to hedge broader implant/medical-device cyclical risk. Expect payoff if wholesale-led margin lift occurs but implant-focused peers continue to face pricing/volume headwinds.
• Hedge FX exposure (ongoing): overlay a modest USD/CHF hedge sized to expected repatriized earnings volatility (e.g., sell CHF forward or buy USD/CHF put options) to protect EPS sensitivity to currency moves that can otherwise turn operational improvements into headline misses.
• Event tactical: buy volatility around near-term corporate catalysts using limited-risk structures (long strangle or calendar spreads) rather than naked calls; keep notional small (0.5–1% of portfolio) because headline FX swings and guidance chatter can produce outsized IV moves.